摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[[(2R,3R,5R)-3,4-dihydroxy-5-(2-methyl-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-methoxyphosphinothioyl] phosphono hydrogen phosphate

中文名称
——
中文别名
——
英文名称
[[(2R,3R,5R)-3,4-dihydroxy-5-(2-methyl-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-methoxyphosphinothioyl] phosphono hydrogen phosphate
英文别名
——
[[(2R,3R,5R)-3,4-dihydroxy-5-(2-methyl-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-methoxyphosphinothioyl] phosphono hydrogen phosphate化学式
CAS
——
化学式
C12H19N4O13P3S
mdl
——
分子量
552.29
InChiKey
WHROSNDONBGBCI-ZLIVQNKWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.7
  • 重原子数:
    33
  • 可旋转键数:
    9
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    273
  • 氢给体数:
    6
  • 氢受体数:
    15

文献信息

  • MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF
    申请人:MODERNA THERAPEUTICS, INC.
    公开号:US20150307542A1
    公开(公告)日:2015-10-29
    The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
    本公开提供了修改的核苷酸,核苷酸和核酸,以及使用它们的方法。
  • TERMINALLY MODIFIED RNA
    申请人:Chakraborty Tirtha
    公开号:US20140147454A1
    公开(公告)日:2014-05-29
    The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
  • ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
    申请人:Moderna Therapeutics, Inc.
    公开号:US20170136131A1
    公开(公告)日:2017-05-18
    The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them.
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    申请人:ModernaTX, Inc.
    公开号:US20180009866A1
    公开(公告)日:2018-01-11
    The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
  • US9597380B2
    申请人:——
    公开号:US9597380B2
    公开(公告)日:2017-03-21
查看更多